NCT06946914

Brief Summary

The aim of our study is to evaluate the efficacy of Misoprostol before elective cesarean section in pregnant women with gestational age less than 38 weeks for preventing the occurrence of neonatal respiratory morbidity.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jun 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2024

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 27, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

May 13, 2025

Status Verified

April 1, 2025

Enrollment Period

1 year

First QC Date

April 21, 2025

Last Update Submit

May 8, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • the incidence of Transient tachypnea of the newborn which defined by increase respiratory rate more than 60 cycle per minute in pregnant women with gestational age less than 38 weeks before elective cesarean section

    in the first 5 minute after delivery of fetus post operative

Study Arms (2)

Misoprostol before elective cesarean section .

ACTIVE COMPARATOR

candidates will receive 100mcg Misoprostol one hour before elective caesarean section.

Drug: Misoprostol

Giving no treatment before elective caesarean section.

PLACEBO COMPARATOR

candidates will receive no treatment before elective caesarean section.

Drug: Misoprostol

Interventions

administration of 100mg of misoprostol to evaluate the efficacy of Misoprostol before elective cesarean section in pregnant women with gestational age less than 38 weeks for preventing the occurrence of neonatal respiratory morbidity.

Giving no treatment before elective caesarean section.Misoprostol before elective cesarean section .

Eligibility Criteria

Age20 Years - 35 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Women with indication for elective caesarean section.
  • Age less than 35 years old.
  • Gestational age less than 38 weeks.
  • Gestational age will be confirmed by certain LMP or reliable early ultrasound measurement of crown-rump length.
  • Singleton pregnancy with no major anomalies

You may not qualify if:

  • Any obstetric disorders as preeclampsia and diabetes.
  • Fetus with oligohydramnios, intrauterine growth restriction.
  • Any contraindications to misoprostol like those with previous allergic reaction or hypersensitivity to prostaglandin hemorrhagic disorders, and severe anemia.
  • History of more than or equal 2 previous caesarean section.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kafr El-sheikh University Hospital

Kafr Ash Shaykh, Egypt, Egypt

RECRUITING

MeSH Terms

Conditions

Respiratory Distress Syndrome

Interventions

Misoprostol

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Intervention Hierarchy (Ancestors)

Prostaglandins E, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Central Study Contacts

Merna Ashraf Ahmed farid, M.B.B.C.H

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
gynaecologist and obsteterician resident

Study Record Dates

First Submitted

April 21, 2025

First Posted

April 27, 2025

Study Start

June 1, 2024

Primary Completion

June 1, 2025

Study Completion

August 1, 2025

Last Updated

May 13, 2025

Record last verified: 2025-04

Locations